Searle & Co. Gilead Sciences, Inc. Transaction History

Searle & Co.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$63.15 - $72.88 $170,505 - $196,776	2,700 Added 66.67%	6,750 $463,000
Q4 2023 Feb 05, 2024	BUY	$73.27 - $83.09 $296,743 - $336,514	4,050 New	4,050 $328,000
Q1 2021 May 12, 2021	SELL	$60.0 - $68.46 $330,000 - $376,529	-5,500 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$56.65 - $64.55 $73,645 - $83,915	1,300 Added 30.95%	5,500 $320,000
Q3 2020 Oct 30, 2020	BUY	$62.1 - $78.08 $260,820 - $327,936	4,200 New	4,200 $265,000
Q2 2018 Jul 19, 2018	SELL	$64.88 - $75.68 $856,415 - $998,976	-13,200 Closed	0 $0
Q4 2017 Jan 17, 2018	SELL	$71.15 - $83.52 $10,672 - $12,528	-150 Reduced 1.12%	13,200 $946,000
Q3 2017 Oct 27, 2017	BUY	$72.11 - $85.47 $962,668 - $1.14 Million	13,350	13,350 $1.08 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Searle & Co., based on Form 13F filings with the SEC.

Stay updated on Searle & Co. with notifications on news.